307. Canavan disease Clinical trials / Disease details


Clinical trials : 6 Drugs : 11 - (DrugBank : 5) / Drug target genes : 2 - Drug target pathways : 2

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04833907
(ClinicalTrials.gov)
April 1, 202124/3/2021rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan DiseasePhase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of AVASPA Gene Therapy for Treatment of Children With Typical Canavan DiseaseCanavan DiseaseDrug: rAAV-Olig001-ASPA;Drug: Levetiracetam;Drug: PrednisoneMyrtelle Inc.NULLActive, not recruiting3 Months60 MonthsAll24Phase 1/Phase 2United States